Dasiglucagon, a next-generation ready-to-use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial.

Tadej BattelinoRamin TehranchiTimothy S Bailey Klemen DovcAnita MelgaardJenine Yager StoneStephanie WoernerThekla von dem BergeLinda A DiMeglio Thomas Danne

Published in: Pediatric diabetes (2021)

Consistent with adult phase 3 trials, dasiglucagon rapidly and effectively restored PG levels following insulin-induced hypoglycemia in children and adolescents with T1DM, with an overall safety profile similar to glucagon.

Keyphrases

type diabetes
glycemic control
randomized controlled trial
study protocol
high glucose
drug induced
diabetic rats
early onset
systematic review
metabolic syndrome
young adults
weight loss
endothelial cells
replacement therapy